Table 1.

c-Src ATP competitive inhibitors.

Drugs	Molecular Targets	Clinical Applications
Bosutinib	BCR-Abl, c-Src, Lyn, Hck, Kit, PDGFR	CML, ALL + clinical trials for breast cancer, glioblastoma
Dasatinib	BCR-Abl, SFKs, Arg, c-KIT, EGFR, PDGFR, DDR1, DDR2, c-FMS, ephrin receptors, TEK, BTK, EphA2	CML + clinical trials for ALL, breast, colorectal, endometrial, head and neck, ovarian, and small cell lung cancers, glioblastoma, melanoma, and NSCLC
Ponatinib	BCR-Abl, SFKs, VEGFR, PDGFR, FGFR, Eph, Kit, RET, Tie2, Flt3	CML, ALL + clinical trials for endometrial, GIST, hepatic biliary, small cell lung, and thyroid cancers
Vandetanib	RET, SFKs, EGFR, VEGFRs, Brk, Tie2, EphR	medullary thyroid carcinoma
Saracatinib (AZD0530)	c-Src, BCR-Abl	Clinical trial for SCLC, NSCLC, colorectal, gastric, ovarian and metastatic osteosarcoma

CML = chronic myelogenous leukemia; ALL = acute lymphoblastic leukemia; GIST = gastrointestinal stromal tumor; SCLC = small cell lung cancer; NSCLC = non-small cell lung cancer.